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Fibroblast growth factor 21 (FGF21) is a metabolic hormone primarily secreted from
the liver and functions in multiple tissues. Various transcription factors induce FGF21
expression in the liver, which indicates that FGF21 is a mediator of multiple environmental
cues. FGF21 alters metabolism under starvation conditions, protects the body from
energy depletion, and extends life span. Pharmacological administration of FGF21
alleviates dyslipidemia and induces weight loss in obese animals. In addition to the
well-studied functions of FG21, several lines of recent evidence indicate a possible link
between FGF21 and non-alcoholic fatty liver disease (NAFLD). High serum levels of FGF21
are associated with NAFLD and its risk factors, such as endoplasmic reticulum stress
and chronic inflammation. In addition, FGF21 alleviates the major risk factors of NAFLD,
including obesity, dyslipidemia, and insulin insensitivity. Thus, FGF21 is a potential drug
candidate for diseases, such as NAFLD, dyslipidemia, and type 2 diabetes. In this review,
the research perspectives of FGF21 and therapeutic potencies of FGF21 as a modulator
of NAFLD are summarized.
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Endocrine FGFs
Fibroblast growth factors (FGFs) constitute a large family of signaling proteins. In vertebrates, 22
members of the FGF family (FGF1-23; mouse FGF15 is an ortholog of human FGF19) have been
identified (1, 2). Most members of this family mainly work as autocrine or paracrine factors by
activating single-pass membrane-spanning FGF receptors (FGFR1–4) on the cell surface in the
presence of heparan sulfate (3, 4). FGF15/19, FGF21, and FGF23 work as hormones by binding
to the FGFR, which requires either β-Klotho for binding of FGF15/19 and FGF21 or Klotho for
FGF23 binding. This distinct mechanism by which the endocrine FGFs alter the binding affinity to
the FGFR and the specific isoforms of FGFRs would explain the tissue specificity of endocrine target
tissues and cell types.
Expression and Secretion of FGF21
Although FGF21 is mainly expressed in the liver, it is also found in the pancreas, white adipose
tissue (WAT), and stressed muscle tissues. Besides being an autocrine/paracrine factor, FGF21 is
also secreted into the bloodstream and acts as a hormone. A recent study revealed that most,
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if not all, of the circulating FGF21 is derived from the liver
(5). Markan et al. showed that plasma FGF21 level was com-
pletely abolished in liver-specific FGF21 knockout mice, whereas
adipose-specific FGF21 knockout mice showed normal levels of
plasma FGF21. FGF21 functions physiologically and pharma-
cologically to maintain energy homeostasis. It improves insulin
sensitivity and glycolipid metabolism and reduces hepatic lipid
accumulation.
Fibroblast growth factor 21 gene transcription in the liver is
regulated by nuclear receptor peroxisome proliferator-activated
receptor (PPAR) α, which plays critical roles in fasting response
(Figure 1) (6–8). Under the regulation of PPARα, hepatic FGF21
mRNA is highly expressed (~20-fold) in fasting mice. Other
reports have shown that the hepatic expression of FGF21 is
also regulated positively or negatively by glucocorticoid recep-
tor (GR) (9), activating transcription factor 4 (ATF4) (10–13),
cAMP-responsive element-binding protein H (CREBH) (14),
carbohydrate response element-binding protein (ChREBP) (15),
PPARγ (16, 17), farnesoid X receptor (FXR) (18), and liver X
receptor (LXR) (19, 20) under various conditions (Figure 1)
[reviewed in Ref. (21)]. In skeletal muscle, the expression of
FGF21was reported to be regulated byATF4 under the conditions
of mitochondrial dysfunction (12) and by PI3K–AKT signaling
pathway (22). In brown adipose tissue (BAT), FGF21 is regulated
by ATF2 (23), while in WAT, it is regulated by PPARγ (24). These
known regulatory pathways indicate diverse FGF21 functions
under the conditions, such as depletion of energy sources, ER
stress, mitochondrial dysfunction, and on exposure to cold envi-
ronment. This reviewwill not only focus on the well-studied func-
tions of FGF21 in glucose and lipid metabolism but also discuss
current reports that suggest a possible link between FGF21 and
fatty liver disease, ER stress or chronic inflammation to present
research perspectives into the novel FGF21 functions in this broad
and developing area of research.
FGF21 in Energy Homeostasis
During the course of starvation, there is a gradual transition
of the energy source of our body from glucose and glycogen
to fat, protein, and acetate (25, 26). Glucose is an important
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FIGURE 1 | Regulations and functions of FGF21 signal representing a possible link between FGF21, non-alcoholic fatty liver disease, endoplasmic
reticulum stress, and chronic inflammation in the liver. FGF21 is expressed in the liver, pancreas, adipose tissue, and muscle in response to various
environmental cues. Several recent evidences indicate that hepatic FGF21 expression is also regulated by endoplasmic reticulum stress, chronic inflammation, and
epigenetics, all of which are correlated with the pathogenesis of non-alcoholic fatty liver disease (NAFLD). Plasma FGF21 is primarily secreted from the liver and acts
in both peripheral organs and the central nervous system as a regulator of multiple biological contexts that improve NAFLD, obesity, dyslipidemia, and insulin
insensitivity.
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energy source for the body, especially for the brain where β-
oxidation of fatty acids is unavailable. During the first stage of
fasting (several hours), glucose is supplied by glycogenolysis. Sub-
sequently, gluconeogenesis occurs to maintain the level of glucose
through various pathways, such as the pathway inwhich phospho-
enolpyruvate carboxykinase (PEPCK) catalyzes the conversion of
oxaloacetate to phosphoenolpyruvate, and the pathway in which
glycerol kinase and glycerol 3-phosphate dehydrogenase catalyze
the conversion of glycerol, a product of adipose tissue lipolysis,
to dihydroxyacetone phosphate. Under prolonged fasting, triglyc-
eride is metabolized into glycerol and free fatty acids through
β-oxidation. The free fatty acids are converted to ATP and acetyl-
coA, which are metabolized to ketone bodies, such as acetone,
acetoacetate, and β-hydroxybutyrate. Ketone bodies are used as
an energy source under severe starvation because long-chain fatty
acids cannot pass through the blood–brain barrier. FGF21 reduces
glycogenolysis and induces β-oxidation, ketogenesis, and gluco-
neogenesis even under normal feeding conditions (6, 27). It is an
important rheostat that shifts the energy source from glycogen
to fat and ketone bodies for survival under energy deprivation
status.
Studies using mice model have revealed that FGF21 induces
lipolysis and maintains plasma glucose level by regulating expres-
sions of hormone-sensitive lipase (HSL) and adipose triglyceride
lipase (ATGL) in WAT and ectopic expressions of pancreatic
lipases in the liver (6). The production of glucose through glu-
coneogenic enzymes, such as PEPCK and glucose-6-phosphatase
(G6Pase), is partially mediated by the transcriptional co-activator
PPAR-γ co-activator-1 α (PGC1-α), whose expression is reg-
ulated by FGF21 (27). Administration of FGF21 to the obese
rodent model was shown to suppress glucose, insulin, and
triglycerides levels in the plasma and triglycerides levels in
the liver, and enhance lipid usage. It has been reported that
FGF21 induces glucose transfer into the adipocytes by increas-
ing GLUT1 expression (28), increases the quantity of pancreatic
islets and insulin secretion from each pancreatic islet (29), and
suppresses plasma glucagon levels (28). FGF21 also exerts anti-
obesity effects through regulation of energy expenditure in BAT
by stimulating sympathetic nerve activity through a mechanism
that depends on the neuropeptide corticotrophin-releasing factor
(CRF) (30).
During prolonged starvation, the body adapts by preserving
critical survival systems, such as heartbeat and brain activity, while
reducing other energy expenditures, including growth, reproduc-
tion, and maintenance of skeletal stature. FGF21 inhibits growth
hormone (GH) signaling by inhibiting the Janus kinase/signal
transducer and activator of transcription (Jak-STAT) signal-
ing pathway (31). This results in suppression of insulin-like
growth factor gene (Igf-1) and other GH target genes in the
liver. FGF21 also inhibits female fertility by suppressing the
vasopressin–kisspeptin signaling cascade at the superchiasmatic
nucleus (SCN) in the hypothalamus, which leads to the inhibition
of the proestrus surge of luteinizing hormone (32). In addition,
FGF21 promotes bone loss (33, 34). This is consistent with a
previous report that FGF21 induces the stimulation of the sympa-
thetic nervous system, which is known to induce bone loss (30).
FGF21 induces a hibernation-like state of reduced body tempera-
ture in rodents called torpor. This is induced by fasting, accom-
panied by increased ketogenesis, and associated with induction
of pancreatic lipases in the liver (6, 35). FGF21 transgenic mice
show all of the above characteristics. Furthermore, transgenic
overexpression of FGF21 in mice extends their lifespan without
having to reduce food intake or affecting the nicotinamide ade-
nine dinucleotide (NAD+) metabolism or AMP-activated protein
kinase (AMPK) and mammalian target of rapamycin (mTOR)
signaling (36). It has also been reported that FGF21 works on
the SCN and dorsal vagal complex of the hindbrain to regulate
circadian rhythm, which is important for the adaptive starvation
response (37). FGF21 has also been reported to be induced in
ground squirrels during hibernation, although the administration
of FGF21 did not induce hibernation in them (38). These facts
indicate that FGF21plays important roles in survival and longevity
by maintaining energy homeostasis.
Besides the induction of torpor by FGF21 under fasting condi-
tions to maintain the energy source, recent reports claim a link
between FGF21 and thermogenesis. Thermogenic stimulations
induce mRNA expression and secretion of FGF21 from BAT (23,
39–42). FGF21 is reported to stimulate browning of the inguinal
WAT in addition to increasing Ucp1 expression in both BAT
and WAT (39, 43–45). The correlation of FGF21 with browning
has been suggested as the mechanism by which FGF21 improves
metabolic disorders, such as obesity and type 2 diabetes. However,
two recent studies using Ucp1-null mice treated with a long-
acting FGF21 analog claim that FGF21 does not require either
UCP1 or browning of WAT to improve body weight and glucose
homeostasis (46, 47). Further investigations would reveal more
details of the role of FGF21 in heat production.
Link Between FGF21 and NAFLD
Non-alcoholic fatty liver disease (NAFLD) is one of the most
common forms of chronic liver diseases; understanding its epi-
demiology and further improvement of its diagnostic evaluation
and treatment is important. NAFLD ranges from hepatic steatosis
(fatty liver) to non-alcoholic steatohepatitis (NASH) and liver
cirrhosis (48). Currently, the pathogenesis of NAFLD is attributed
to a multi-hit process that involves lipotoxicity, oxidative stress,
ER stress, a chronic inflammatory state, and mitochondrial dys-
function. The major risk factors for NAFLD are obesity, dyslipi-
demia, and insulin insensitivity, which have been shown to be
improved by FGF21. FGF21 reverses hepatic steatosis, counteracts
obesity, and improves insulin insensitivity (48). Methionine- and
choline-deficient diet (MCD) is a model for NASH in rodents
(49). It is also known that methionine-deficient diet enhances
lipolysis in WAT, and decreases glucose (49, 50). MCD as well
as FGF21 increase ATGL and HSL activities in all adipose depots
(51). In addition, high serum levels of FGF21 are associated with
hepatic steatosis (52–56). These facts indicate that FGF21 level is
regulated under the NAFLD condition and may be involved in
the protection fromNAFLD progression by reversing the steatosis
and improving the metabolic energy status (Figure 1). FGF21
has preventive function against lipotoxicity, oxidative stress, ER
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stress, and chronic inflammatory state, although the mechanisms
underlying its functions are mostly unknown.
Epigenetic Regulation of FGF21 During
Development of NAFLD
Although the increased hepatic FGF21 expression is thought
to be responsible for the elevated serum levels of FGF21 in
patients with NAFLD (10), the underlying molecular mechanism
is unclear. Besides the FGF21 induction seen in theMCD-induced
NASH model, the methionine-deficient only diet also increases
FGF21 in the serum of rodents (49, 50). This interesting finding
suggests that a methionine-dependent epigenetic regulation of
FGF21 transcription might be involved in the pathogenesis and
prevention of NAFLD (Figure 1). It is known that intracellu-
lar metabolites, including S-adenosyl-methionine (SAM), a-KG,
flavin adenosine dinucleotide (FAD), acetyl-CoA, and NAD+, are
required as substrates for epigenetic modifying enzymes (57, 58).
SAM is a methyl donor required for the maintenance of DNA
methylation and histone methylation.
ER Stress and FGF21
The endoplasmic reticulum (ER) plays a crucial role in the folding
of proteins and only properly folded proteins are transported to
the Golgi apparatus. ER stress is induced by the accumulation
of unfolded and/or misfolded proteins in the ER lumen and
causes the unfolded protein response (UPR) of the cell. The UPR
restores ER homeostasis and function by halting protein transla-
tion, degrading misfolded proteins, and activating signaling path-
ways to increase chaperones for protein folding. ER stress plays a
critical role in metabolic homeostasis, as shown in a number of
diseases, including NAFLD, obesity, and type 2 diabetes. Recent
studies have shown that both triglycerides- and tunicamycin-
induced ER stress stimulates FGF21 expression in hepatocytes
and serum levels of FGF21 (10, 59–62). Among the three major
transducers of the UPR, namely PERK, IRE1, and ATF6, FGF21
is reported to be regulated by PERK and IRE1 (10). Activation
of PERK inactivates the translation initiation factor eIF2α by
phosphorylation at Ser51. This inactivation paradoxically induces
translation of the transcription factor ATF4, which directly regu-
lates FGF21 expression through two binding sites in the FGF21
promoter region. In addition to transcriptional regulation by
ATF4, FGF21 is also directly regulated by proapoptotic protein
CCAAT enhancer binding protein homologous protein (CHOP)
and XBP1 (59, 61). Activation of IRE1, which is a transducer of
UPR, generates an active form of transcription factor XBP1 by
inducing site-specific splicing and in turn induces FGF21 expres-
sion (61). In addition, transcription of β-Klotho coding gene
(klb) is associated with increased ER stress in diet-induced obese
patients and rodents, and ATF4 signaling pathway is essential for
induction of the gene expression of klb, which is mediated by ER
stress (63). These findings suggest that FGF21 is a possible link
between increased cellular stress and NAFLD (10). However, the
detailed mechanism underlying the FGF21 function in NAFLD
still needs to be elucidated.
FGF21 and Its Role in Chronic and Acute
Inflammation
The pathogenesis of NAFLD is partially attributed to a chronic
inflammatory state. FGF21 may be associated with the chronic
inflammation in NAFLD. PPARα, the potent FGF21 regulator in
the liver, regulates the expression of genes involved in chronic
inflammation as well as fatty acid metabolism in the liver. In the
heart, an elective cardiac surgery that induces systemic inflam-
matory response is accompanied by a marked increase in cir-
culating FGF21, TNF-α, and insulin levels (64). Serum FGF21
levels are also higher in seropositive rheumatoid arthritis (RA)
compared with seronegative RA (65). In type 2 diabetic rat mod-
els, FGF21 administration ameliorates inflammation biomarkers
(66). In terms of FGF21 signaling, inflammatory cytokine TNF-
α impairs FGF21 signal by suppressing the expression of β-
Klotho in adipocytes (67). These findings point to a potential
link between FGF21 and chronic inflammation in the microvas-
culature. In the acute phase response (APR), FGF21 is reported
to modulate the levels of ketone bodies and free fatty acids in
response to lipopolysaccharide (LPS) and is protective against
the toxic effect of LPS and sepsis. APR inducers, such as LPS,
zymosan, and turpentine, increase FGF21 expression in the adi-
pose tissue,muscle, and serum,while they suppress FGF21 expres-
sion in the liver (68). These observations suggest that FGF21 is
closely involved in the inflammatory response, although these
expression regulations of FGF21 by APR are not observed in the
cell culturemodels. It is possible that LPS-induced liver injurymay
affect both synthesis and degradation of FGF21 in the liver.
Concluding Remarks
Fibroblast growth factor 21 is an important regulator of
metabolism and is a potential therapeutic drug candidate. In
addition to its therapeutic benefits, FGF21 could be a prognostic
indicator and/or diagnostic marker of metabolic imbalance and
other homeostatic disorders. FGF21 is reported to be involved in
various pathological conditions, including fatty liver disease, ER
stress, and chronic inflammation, as discussed in this manuscript.
Despite themultitude of effects of FGF21, whether administration
or induction of FGF21 or activation of FGFRs could be pharmaco-
logically beneficial is still controversial. While metabolic profiles
are drastically improved by FGF21 in obese rodent models, the
results considerably differ among species, thus questioning the
appropriateness of FGF21 for the treatment of human diseases,
such as obesity, hyperlipidemia, and type 2 diabetes (2). Gaich
et al. studied the effects of an FGF21 analog in a randomized,
placebo-controlled, double-blind, proof-of-concept trial in obese
human patients with type 2 diabetes (69). They showed that a 28-
day treatment with the FGF21 analog LY2405319 (LY) improved
the plasma levels of low-density lipoprotein cholesterol, triglyc-
erides, high-density lipoprotein cholesterol, and fasting insulin in
these patients.
It is necessary to establish the appropriate concentration range
of FGF21 for its therapeutic administration, since serum FGF21
concentrations show wide individual variation (2). Galman et al.
reported that the fasting serum FGF21 levels checked in the
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morning in 76 healthy subjects are varied 250-fold from 21 to
5300 pg/ml (70). The serum FGF21 levels in patients with NAFLD
or type 2 diabetes were also within the range (52, 71). The diurnal
variation of FGF21 is still controversial (2), while a previous study
has reported that FGF21 concentration in humans peaks in the
early morning (72). Gaich et al. reported that the mean con-
centration of LY, which is indistinguishable from native FGF21,
increased in a dose-dependent manner and was 10- to over 100-
fold greater than that observed in the previous reports mentioned
above (2, 69, 71).
Because FGF21 has various physiological and pharmacologi-
cal functions, the large dose of FGF21 required for its in vivo
functions could cause unexpected side effects. There are several
concerns with regard to the side effects of FGF21 [reviewed in
Ref. (73, 74)]. FGF21 inhibits GH–IGF1 axis in the liver (31)
and antagonize the effects of GH in chondrocytes (75), raising
the possibility that FGF21 blocks somatic growth. It also pro-
motes bone loss in mice models indicating a risk of inducing
osteoporosis (33). As previously mentioned in this manuscript,
FGF21 also inhibits female fertility (32). Therefore, further stud-
ies to elucidate the physiological and pharmacological roles of
FGF21 in detail are warranted so as to provide important insights
for the use of FGF21 as therapeutic drugs to treat metabolic
disorders.
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